Studies from Stanford University in the Area of Diplopia Reported (Teprotumumab-related Adverse Events In Thyroid Eye Disease a Multicenter Study).

A new report discusses research findings on the adverse events (AEs) associated with teprotumumab treatment in patients with thyroid eye disease (TED). The study, conducted at six tertiary centers, evaluated 131 patients and found that proptosis improved in 77% of patients, with an average improvement of 3.0 mm. Adverse events occurred in 81.7% of patients, with most being mild and reversible. However, serious AEs were also reported, leading to treatment discontinuation in some cases. The researchers recommend that treating physicians inform patients about the risks, closely monitor patients throughout therapy, and be prepared to manage AEs if they occur. [Extracted from the article]